ArticleMicrosystems & nanoengineering2026
A wearable closed-loop insulin micropump toward a miniaturized artificial pancreas for diabetes.
Article in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The application of a fully autonomous artificial pancreas faces fundamental constraints from the bulky mechanical drives of conventional insulin pumps and the spatially separated glucose sensing unit. Herein, we report a wearable closed-loop insulin micropump that enables a miniaturized artificial pancreas for diabetes treatment. It seamlessly integrates an electrochemical micropump with an optical glucose-responsive microneedle (MN) sensor. The core actuation module features a novel semi-dry sandwich electrode configuration combined with a highly elastic latex membrane and a groove-type epoxy sealing architecture. This structural paradigm shift effectively eliminates bulk fluid flow and ensures robust hermeticity for precise, electrolysis-gas-driven, microliter-scale dosing with a precision of 0.5 μL. For continuous glucose monitoring, a polyvinylpyrrolidone/polyvinyl alcohol (PVP/PVA) hydrogel MN array functionalized with 9-anthracene boronic acid (9-ANB) is employed. The specific binding of interstitial glucose triggers measurable fluorescence quenching, which is precisely digitized by an integrated XYZ true-color sensor (detection range: 0-600 mg/dL). Comprehensive in vitro and in vivo evaluations demonstrate the platform's predictable, programmable delivery kinetics and excellent biocompatibility. In type 1 diabetic mouse models, a smartphone-controlled system by autonomously and effectively suppressed postprandial glycemic spikes, maintaining glycemic fluctuations within 25 mg/dL. This highly integrated, miniaturized design offers a compelling paradigm shift for next-generation, patient-friendly diabetes management systems.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.